Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NVCT
NVCT logo

NVCT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Nuvectis Pharma Inc (NVCT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.750
1 Day change
-4.32%
52 Week Range
13.340
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

NVCT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks a strong bullish catalyst, has no recent news-driven momentum, and the proprietary trading signals show no buy setup today. The technical picture is mixed-to-weak, so the best call is to hold off rather than buy at the current pre-market price around 9.99-10.19.

Technical Analysis

NVCT is trading near the S1 support zone at 9.999, which makes the current level technically relevant, but the broader setup is not bullish. MACD histogram is -0.162 and still negatively expanding, showing downside momentum. RSI_6 at 42.872 is neutral to slightly weak, not signaling oversold strength. Moving averages are converging, which usually reflects indecision rather than a clear uptrend. The stock trend model is also not strongly favorable, with only a 30% chance of a modest next-day move and limited near-term upside confidence.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is extremely bullish on paper because the put-call ratios are very low. Open interest put-call ratio at 0.02 and option volume put-call ratio at 0.0 indicate calls overwhelmingly dominate puts. However, actual option volume today is tiny (9 contracts), so the sentiment signal is weak in practical terms. Implied volatility is very high at 232.92, which implies elevated speculation rather than stable long-term confidence. Overall, options data leans bullish but is not strong enough to override the weak technical setup.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
8

Positive Catalysts

  • ["Options positioning is heavily call-skewed, suggesting speculative bullish sentiment.", "Current price is close to support around 9.999, which may attract short-term buyers.", "The stock trend model shows some potential for a positive move over the next month."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no current event-driven catalyst.", "AI Stock Picker shows no signal today.", "SwingMax shows no recent buy signal.", "MACD is bearish and worsening.", "RSI is neutral, not indicating strong accumulation.", "No recent hedge fund or insider buying trends.", "No recent congress trading data.", "No financial snapshot was available, limiting visibility into fundamental momentum."]

Financial Performance

Financial data for the latest quarter is unavailable because the snapshot returned an error, so there is no reliable quarterly revenue or earnings growth assessment. The latest quarter season cannot be confirmed from the provided data. Because of that, there is no fundamental evidence here to support an immediate long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible recent Wall Street upgrade/downgrade trend to support the stock. Based on the available information, the pros view is limited because there are no new bullish analyst catalysts, while the cons view is stronger due to weak momentum, no news catalyst, and no insider or hedge fund accumulation. Overall Wall Street sentiment cannot be called bullish from the current dataset.

Wall Street analysts forecast NVCT stock price to rise
3 Analyst Rating
Wall Street analysts forecast NVCT stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.190
sliders
Low
10
Averages
15.67
High
20
Current: 10.190
sliders
Low
10
Averages
15.67
High
20
H.C. Wainwright
Buy
downgrade
$15 -> $10
AI Analysis
2025-08-04
Reason
H.C. Wainwright
Price Target
$15 -> $10
AI Analysis
2025-08-04
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Nuvectis Pharma to $10 from $15 and keeps a Buy rating on the shares. The firm removed NXP800 from its projections. The deprioritization of NXP800 allows Nuvectis to better deploy capital in assets with a greater chance of success in the clinic, the analyst tells investors in a research note.

People Also Watch